Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Researchers assessed the prognostic significance of older age and comorbidity burden on overall survival in patients with hepatocellular carcinoma.

The FDA has granted Fast Track designation to amezalpat (TPST-1120) for the treatment of patients with hepatocellular carcinoma.

Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

Further exploration of these findings will provide valuable insights into how our cells stay healthy and open up exciting possibilities toward improved health.

Like many rare diseases, fibrolamellar hepatocellular carcinoma (FLC) mounts a ferocious attack against ... a senior researcher in the lab. “Ideally, our findings will refine the detection of the ...

Like many rare diseases, fibrolamellar hepatocellular carcinoma (FLC ... "Ideally, our findings will refine the detection of the disease, change the course of treatment, and increase patient ...

1The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York. 2Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.